Yuhan stock: CEO succession talks keep R&D chief in focus

Published on 11/06/2026 at 02:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yuhan stock faces an extended CEO succession process after the board deferred a final choice. R&D chief Kim Yeolhong is emerging as a central candidate.

Yuhan weighs its next leadership model

The board discussed succession procedures but did not select a candidate at its October 28 meeting.
Kim Yeolhong is gaining attention as a possible successor to CEO Cho Uk-je.
Kim's priorities include new anticancer drugs, external biotech cooperation and longer-term R&D expansion.

Yuhan, KR7000100008, Illustration mit AI erstellt.

Yuhan's board has not yet chosen the company's next chief executive, keeping research and development head Kim Yeolhong at the center of the succession debate. The Chosun Daily reported on November 6 that Yuhan discussed the appointment process at its October 28 board meeting but did not finalize a candidate.

Succession process remains unresolved

CEO Cho Uk-je's current term ends on March 15, 2027. Yuhan has traditionally prepared internal candidates through a staged promotion and management-training process, but that framework is complicated by Kim's existing position as chief president after joining the company in 2023.

The board reportedly spent more than six hours discussing how the succession process and management structure could change if Kim becomes the next representative. Internal candidates Lee Byeong-man and Yoo Jae-cheon remain part of the discussion, while a single-CEO model and a co-CEO structure are both being considered.

R&D strategy shapes the debate

Kim has recently presented Yuhan's medium- and long-term strategy at external events. He said the company aims to become one of the world's top 50 pharmaceutical companies and plans to launch at least one anticancer drug in South Korea each year from 2027 through 2030.

The strategy centers on building follow-on oncology candidates after Leclaza and using internally generated revenue to cover the full R&D budget by 2031. Kim also highlighted cooperation with outside biotechnology firms, suggesting that the next leadership model will be closely tied to pipeline development and open innovation.

Company profile and industry position

Yuhan is a South Korean pharmaceutical company focused on prescription medicines and the development of new drugs, with oncology at the center of its follow-on pipeline. Its strategy combines domestic commercialization with ambitions for broader international pharmaceutical scale. The report also names biotech companies Kangstem Biosciences and Inventage Lab as external counterparts in discussions about technology cooperation, while Yuhan remains the established pharmaceutical company leading its own drug-development program.